Skip to main content
Luye Pharma Group Limited logo

Luye Pharma Group Limited — Investor Relations & Filings

Ticker · 2186 HKEX Manufacturing
Open in API
Filings indexed 1,503 across all filing types
Latest filing 2025-05-19 Report Publication Anno…
Country HK Hong Kong
Listing HKEX 2186

About Luye Pharma Group Limited

http://www.luye.cn

Luye Pharma Group is an international pharmaceutical company dedicated to the research, development, manufacturing, and commercialization of innovative medications, novel formulations, and biopharmaceutical products. The company's core strategy emphasizes advanced drug delivery systems, including microspheres, liposomes, and transdermal technologies, to enhance therapeutic efficacy and patient compliance. Luye Pharma maintains a strong focus on key therapeutic areas, particularly the Central Nervous System (CNS). Its portfolio includes proprietary products such as Roxinlin® (Toludesvenlafaxine extended-release tablets) and various long-acting injectable antipsychotic formulations, positioning the group as a global pharmaceutical enterprise.

Recent filings

Filing Released Lang Actions
DATE OF BOARD MEETING
Report Publication Announcement Classification · 85% confidence The document is a short HKEX announcement notifying investors of the date of an upcoming board meeting to approve the annual results and consider dividend payment. It does not contain any financial results itself or any substantive report, nor does it announce changes in directors. It merely sets the timing for the report approval and release. Under our taxonomy, this is an announcement regarding the timing of a company report publication (Report Publication Announcement).
2025-05-19 English
Monthly Return of Equity Issuer on Movements in Securities
Regulatory Filings Classification · 90% confidence The document is a “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” under HKEX Listing Rules, detailing movements in authorized, issued, and treasury shares for the month ended 30 April 2025. It is a periodic regulatory submission (Form FF301) rather than an annual or interim financial report, earnings release, or management presentation. It is the actual regulatory return itself, not merely an announcement of a report’s publication. No other specific category (e.g., share issue, buyback, merger) fits precisely; thus it defaults to the general Regulatory Filings category.
2025-05-12 English
Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 April 2025
Regulatory Filings Classification · 90% confidence The document is a Form FF301 “Monthly Return for Equity Issuer and Hong Kong Depositary Receipts” filed under HKEX Listing Rule Chapter 19B. It provides detailed data on movements in authorised share capital, issued shares, convertibles, etc., for the month. It is not a management discussion, earnings release, AGM material, nor an annual or interim report. It is a routine regulatory filing to the exchange. No more specific category covers a monthly return under Listing Rules, so it falls into the fallback ‘Regulatory Filings’ category (RNS).
2025-05-07 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 93% confidence The document is a formal notice to shareholders of Luye Pharma Group Ltd. of its upcoming Annual General Meeting, detailing the date, resolutions for shareholder approval (including director re-elections, mandates to issue and repurchase shares), proxy instructions, and closing of the register. This is a proxy solicitation and information statement providing shareholders with information and requesting votes for the AGM.
2025-04-29 English
FORM OF PROXY FOR USE AT ANNUAL GENERAL MEETING TO BE HELD ON 28 MAY 2025
Proxy Solicitation & Information Statement Classification · 90% confidence The document is a Form of Proxy for use at the Annual General Meeting, including instructions on how shareholders appoint proxies and vote on resolutions. This is part of the materials sent to shareholders to solicit their votes and provide information ahead of the AGM. It is not the AGM presentation itself, nor the notice announcing publication of another report. It fits the definition of a Proxy Solicitation & Information Statement (PSI).
2025-04-29 English
PROPOSALS FOR GENERAL MANDATES TO ISSUE SHARES AND REPURCHASE SHARES AND RE-ELECTION OF RETIRING DIRECTORS INCLUDING INDEPENDENT NON-EXECUTIVE DIRECTOR WHO HAS SERVED MORE THAN NINE YEARS ON THE BOARD
Proxy Solicitation & Information Statement Classification · 88% confidence The document is a detailed shareholder circular for the Annual General Meeting of Luye Pharma Group Ltd., containing proposals (general mandates to issue and repurchase shares, director re-elections), explanatory statements, appendices on director details, and the formal notice of the AGM with a proxy form. It is a proxy solicitation and information statement sent to shareholders to request votes, exactly matching the definition of a Proxy Solicitation & Information Statement.
2025-04-29 English

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.